安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2014年
8期
1486-1487,1488
,共3页
大肠癌%人类表皮生长因子受体-2%预后%相关性
大腸癌%人類錶皮生長因子受體-2%預後%相關性
대장암%인류표피생장인자수체-2%예후%상관성
colorectal cancer%HER-2%prognosis%relationship
目的:研究人类表皮生长因子受体-2(HER-2)在大肠癌患者中的表达及特征,了解其与患者预后的相关性。方法采用免疫组化法检测121例大肠癌组织及66例正常大肠组织中HER-2的表达情况,比较大肠癌组织中不同的病理特征和临床资料与HER-2表达的相关性。结果正常组织中HER-2表达阳性12例(18.2%),大肠癌组织中阳性46例(38.0%),两组比较差异有统计学意义(P<0.05);HER-2的表达与年龄、性别、肿瘤直径和部位、远端转移无关(P>0.05),与分化程度、分期、淋巴结转移有明显的相关性(P<0.05)。HER-2高表达的大肠癌患者5年生存率低于低表达患者(P<0.05)。结论HER-2的表达与大肠癌的发生有关,可以作为早期检测及评价预后的标志。
目的:研究人類錶皮生長因子受體-2(HER-2)在大腸癌患者中的錶達及特徵,瞭解其與患者預後的相關性。方法採用免疫組化法檢測121例大腸癌組織及66例正常大腸組織中HER-2的錶達情況,比較大腸癌組織中不同的病理特徵和臨床資料與HER-2錶達的相關性。結果正常組織中HER-2錶達暘性12例(18.2%),大腸癌組織中暘性46例(38.0%),兩組比較差異有統計學意義(P<0.05);HER-2的錶達與年齡、性彆、腫瘤直徑和部位、遠耑轉移無關(P>0.05),與分化程度、分期、淋巴結轉移有明顯的相關性(P<0.05)。HER-2高錶達的大腸癌患者5年生存率低于低錶達患者(P<0.05)。結論HER-2的錶達與大腸癌的髮生有關,可以作為早期檢測及評價預後的標誌。
목적:연구인류표피생장인자수체-2(HER-2)재대장암환자중적표체급특정,료해기여환자예후적상관성。방법채용면역조화법검측121례대장암조직급66례정상대장조직중HER-2적표체정황,비교대장암조직중불동적병리특정화림상자료여HER-2표체적상관성。결과정상조직중HER-2표체양성12례(18.2%),대장암조직중양성46례(38.0%),량조비교차이유통계학의의(P<0.05);HER-2적표체여년령、성별、종류직경화부위、원단전이무관(P>0.05),여분화정도、분기、림파결전이유명현적상관성(P<0.05)。HER-2고표체적대장암환자5년생존솔저우저표체환자(P<0.05)。결론HER-2적표체여대장암적발생유관,가이작위조기검측급평개예후적표지。
Objective To investigate the expression of HER-2 in patients with colorectal cancer and the relationship between its expres-sion and patients,prognosis.Methods Immunohistochemistry was used to detect the expression of HER-2 in 121 cases of colorectal cancer tissue and 66 cases of normal colorectal tissue.Pathological characteristics and clinical data were compared between those two groups.Results HER-2 was positively expressed in 12 cases (18.2%)of normal tissue and 46 cases (38.0%)of colorectal cancer tissue,and the difference was statistically significant (P<0.05).The overexpression of HER-2 was not associated with patients,age, gender,tumor size,location and distant metastases (P>0.05 ),but associated with differentiation stage,Dukes, stage and lymphatic metastases (P<0.05 ).The colorectal cancer patients with overexpression of HER-2 had a significantly lower five-year survival than those with low expression (P<0.05).Conclusions The expression of HER-2 was associated with the occurrence of colorectal cancer, which could be used as a marker for early detection and prognosis.